Page 5, lines 28 and 29 please delete "the subject of the subsidiary claims" and substitute --described herein-- therefor.

IN THE CLAIMS:

Please amend claim 1 as follows.

A1

1. (Amended) Transdermal system for the delivery of clonidine[, characterised in that it comprises] comprising a clonidine-containing contact adhesive layer based on a 2-ethylhexyl acrylate/vinyl acetate copolymer.

Please cancel claims 2-15 in accordance with the preliminary amendment of November 29, 1999, and substitute therefor the following new claims 16-29:

16. Transdermal system of claim 1 wherein the contact adhesive layer comprises clonidine in a concentration range of from 0.1 to 20% by weight.

A2

17. Transdermal system of claim 16 wherein the contact adhesive layer comprises clonidine in a concentration range of from 2 to 10% by weight.

112

18. Transdermal system of claim 1 wherein the contact adhesive layer further comprises at least one

element selected form the group consisting of fillers, skin-protective substances, and tackifiers.

19. Transdermal system of claim 1 wherein the clonidine-containing contact adhesive layer forms a layer of a planar self-adhesive patch of multi-layered structure.

20. Transdermal system of claim 19 wherein the patch also has a covering and, on a side opposite from the covering, a removable support that temporarily covers the contact adhesive layer.

21. Transdermal system of claim 20 wherein the covering is selected from the group consisting of plastic film, plastic foam, woven fabric, and non-woven fabric.

22. Transdermal system of claim 20 wherein the support is of plastic film, paper, or a laminate of plastic film and paper.

23. Transdermal system of claim 22 wherein the support is siliconized.

24. Transdermal system of claim 21 wherein the support comprises a polyester film, polyethylene film, or polypropylene film.

25. Transdermal system of claim 19 wherein the dry contact adhesive layer has a weight per unit area of from 20 g/m^2 to 150 g/m^2.

26. Transdermal system of claim 25 wherein the dry contact adhesive layer has a weight per unit area of from 50 g/m^2 to 120 g/m^2.

27. Transdermal system of claim 1 wherein the delivery rate is from 10 μg to 1000 μg of clonidine per day.

28. Transdermal system of claim 27 wherein the delivery rate is from 50 μg to 500 μg of clonidine per day.

29. Method of treating a disorder selected from the group consisting of hypertension, migraine, anxiety states, hyperkinetic behavioral disorders, withdrawal symptoms in alcohol or drug withdrawal, and menopausal symptoms, said method comprising the step of administrating clonidine to a patient in need of such